AMAG Pharmaceuticals Inc

AMAG Pharmaceuticals — JP Morgan 38th Healthcare Conference 2020

33 slides from AMAG Pharmaceuticals's conference presentation, Jan 9, 2020

  1. Slide 1: AMAG Pharmaceuticals JP Morgan 38th Healthcare Conference January 2020

    Slide 1: AMAG Pharmaceuticals JP Morgan 38th Healthcare Conference January 2020

    AMAG Pharmaceuticals JP Morgan 38th Healthcare Conference January 2020 © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 1

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward‐looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, 2019

  3. Slide 3: 2019 In Review

    Slide 3: 2019 In Review

    2019 In Review 3

  4. Slide 4: AMAG's 2019 Year In Review

    Slide 4: AMAG's 2019 Year In Review

    AMAG's 2019 Year In Review Option 4 Completed acquisition of Perosphere Pharmaceuticals and added ciraparantag to development portfolio Grew Feraheme to record revenue of $167M-$169M and achieved Q4 market share of 17.7%1 • IM supply disruptions resulted in removal of both brand and authorized gener

  5. Slide 5: 2019 Financial Results

    Slide 5: 2019 Financial Results

    2019 Financial Results Preliminary and unaudited ($M) Actual Preliminary Preliminary Guidance 9-months 2019 Q4-2019 FY 2019 FY 2019 Revenue Feraheme $126 $40 - $42 $167- 169 -- Makena 97 24 - 27 120 - 123 -- Intrarosa 15 6.5 21 -- Other product revenue -- (0.5) (1) -- Collaboration revenue1 -- 16 16

  6. Slide 6: Recently Announced News – January 9, 2020

    Slide 6: Recently Announced News – January 9, 2020

    Recently Announced News – January 9, 2020 6

  7. Slide 7: Experienced Leadership Team Committed to Realize AMAG's Potential

    Slide 7: Experienced Leadership Team Committed to Realize AMAG's Potential

    Experienced Leadership Team Committed to Realize AMAG’s Potential Leadership Transition William Heiden will step down as • AMAG’s Board of Directors has initiated a search for his successor, which it expects to complete by mid-2020 President and Chief Executive Officer • Mr. Heiden will remain in hi

  8. Slide 8: Current Portfolio Valuable but Requires Extensive Resources

    Slide 8: Current Portfolio Valuable but Requires Extensive Resources

    Current Portfolio Valuable but Requires Extensive Resources PHYSICIAN/CONSUMER(DTC) PHYSICIAN DRIVEN DRIVEN Hematology Maternal Health Women’s Health COMMERCIAL Divest PIPELINE Ciraparantag AMAG-423 Divest Vyleesi and Intrarosa Completed strategic review of product portfolio • Vyleesi launch is off

  9. Slide 9: Streamlined Portfolio and Infrastructure Positions AMAG for Profitability

    Slide 9: Streamlined Portfolio and Infrastructure Positions AMAG for Profitability

    Streamlined Portfolio and Infrastructure Positions AMAG for Near- and Long-term Profitability PHYSICIAN DRIVEN PORTFOLIO Hematology Maternal Health SNAPSHOT 2020 COMMERCIAL PIPELINE Ciraparantag AMAG-423 Feraheme • Provides continued growth and positive cash flow ‒ Sufficient to fund pipeline assets

  10. Slide 10: 2020 Financial Guidance Reflects a Return to Positive Adjusted EBITDA

    Slide 10: 2020 Financial Guidance Reflects a Return to Positive Adjusted EBITDA

    2020 Financial Guidance Reflects a Return to Positive Adjusted EBITDA 2020 FINANCIAL GUIDANCE1 ($M) Total revenue $230 - $280 Operating income2 $2 - $32 Adjusted EBITDA3 $20 - $50 Continued growth of Risk-adjusted topline view of Significant reduction in Feraheme to fund the Makena given the uncerta

  11. Slide 11: Core Value Drivers: 2020 and Beyond

    Slide 11: Core Value Drivers: 2020 and Beyond

    Core Value Drivers: 2020 and Beyond 11

  12. Slide 12: Feraheme (ferumoxytol injection)

    Slide 12: Feraheme (ferumoxytol injection)

    Feraheme® (ferumoxytol injection) 12

  13. Slide 13: Continued Strong Feraheme Performance

    Slide 13: Continued Strong Feraheme Performance

    Continued Strong Feraheme Performance1 $200 Consistent Revenue Growth $100 Revenue ($M) $0 2017 2018 2019 • Build on strong performance of past years, including record annual 2019 revenues 300,000 − Performance-based contracting drives volume, Consistent with stable price Volume 200,000 Growth 100,0

  14. Slide 14: Makena (hydroxyprogesterone caproate injection)

    Slide 14: Makena (hydroxyprogesterone caproate injection)

    Makena® (hydroxyprogesterone caproate injection) 14

  15. Slide 15: Preterm Birth is a Significant Public Health Issue in the U.S.

    Slide 15: Preterm Birth is a Significant Public Health Issue in the U.S.

    Preterm Birth is a Significant Public Health Issue in the U.S. MEIS TRIAL PROLONG TRIAL Conducted in U.S. patient population Conducted primarily in non-U.S. which had a high rate of preterm birth patient population Demonstrated a Did not show a reduction in preterm birth rates 30% reduction Lower ri

  16. Slide 16: Managing Makena to Remain Cash Flow Positive in 2020

    Slide 16: Managing Makena to Remain Cash Flow Positive in 2020

    Managing Makena to Remain Cash Flow Positive in 2020 Subcutaneous Auto-injector • Well established in the marketplace ‒ Entered 2020 with a strong market share for subcutaneous auto-injector of 63% • Uncertainty surrounding Makena’s future following AdCom meeting ‒ AdCom meeting outcome negatively i

  17. Slide 17: Development Pipeline Ciraparantag

    Slide 17: Development Pipeline Ciraparantag

    Development Pipeline Ciraparantag 17

  18. Slide 18: Novel Oral Anticoagulant (NOAC) Use Growing

    Slide 18: Novel Oral Anticoagulant (NOAC) Use Growing

    Novel Oral Anticoagulant (NOAC) Use Growing Improved reversal agents could lead to even broader NOAC use Anticoagulants (often referred to as blood thinners) reduce the ability of the blood to form clots • Prevention of stroke in patients with nonvalvular atrial fibrillation • Prevention and treatme

  19. Slide 19: Anticoagulants and Need for Reversal Agents

    Slide 19: Anticoagulants and Need for Reversal Agents

    Anticoagulants and Need for Reversal Agents Ciraparantag: in development as an anticoagulant reversal agent • Use of NOACs and LMWH increase risk of serious bleeding complications (1.5%-2% of patients per year)1 • To manage bleeding, a reversal agent may be critical in cases such as: Emergency/urgen

  20. Slide 20: Large Unmet Medical Need with Significant Global Commercial Potential

    Slide 20: Large Unmet Medical Need with Significant Global Commercial Potential

    Large Unmet Medical Need with Significant Global Commercial Potential Large unmet medical need • Opportunity to provide an improved reversal agent to NOACs Numerous characteristics suggest U.S. market opportunity ciraparantag may offer a more optimal reversal agent 2 • Ready to use ~6 Million ~150,0

  21. Slide 21: Phase 2b Study of Ciraparantag: Reversal of Xarelto

    Slide 21: Phase 2b Study of Ciraparantag: Reversal of Xarelto

    Phase 2b Study of Ciraparantag: Reversal of Xarelto® Rapid and sustained reversal of NOACs in healthy volunteer study Mean Whole Blood Clotting Time (WBCT) by Timepoint Individual Responder Analysis (n=12 per dose) Ciraparantag or placebo dose 1 100.0% 40% Placebo 100% Baseline +3 days of Ciraparant

  22. Slide 22: Whole Blood Clotting Time (WBCT) is a Good Measure of Anticoagulation

    Slide 22: Whole Blood Clotting Time (WBCT) is a Good Measure of Anticoagulation

    Whole Blood Clotting Time (WBCT) is a Good Measure of Anticoagulation • WBCT is a measure of the time it takes for blood to clot – clinically relevant physiologic outcome Perosphere Technologies’ broad spectrum 1 – WBCT is currently evaluated manually Point-of-Care coagulometer – Anticoagulant activ

  23. Slide 23: AMAG-423

    Slide 23: AMAG-423

    AMAG-423 23

  24. Slide 24: Severe Preeclampsia: Significant Unmet Medical Need Globally

    Slide 24: Severe Preeclampsia: Significant Unmet Medical Need Globally

    Severe Preeclampsia: Significant Unmet Medical Need Globally AMAG-423 (Digoxin Immune Fab: DIF) in development for the treatment of severe preeclampsia Preeclampsia is the Maternal morbidity Adverse neonatal leading cause of: and mortality outcomes No effective treatments FDA granted AMAG-423 Signif

  25. Slide 25: Large Unmet Medical Need with Significant Global Commercial Potential

    Slide 25: Large Unmet Medical Need with Significant Global Commercial Potential

    Large Unmet Medical Need with Significant Global Commercial Potential Annual U.S. incidence of Annual U.S. incidence of preeclampsia SEVERE preeclampsia Large unmet medical need ~140,000 ~50,000 pregnant women1 pregnant women2 Potential ex-U.S. opportunities Every 1% of patients with severe preeclam

  26. Slide 26: Strong Scientific Rationale for AMAG-423

    Slide 26: Strong Scientific Rationale for AMAG-423

    Strong Scientific Rationale for AMAG-423 Reverses effect of EDLFs on sodium pump activity MECHANISM OF ACTION • Endogenous digitalis-like factors (EDLFs) are 30 DEEP Trial4: Sodium Pump Activity circulating inhibitors of the Na+ K+ ATPase pump 25 (Surrogate for EDLF Activity) (“sodium pump”) and whe

  27. Slide 27: DEEP Trial: Improvements in Select Neonatal Outcome Measures

    Slide 27: DEEP Trial: Improvements in Select Neonatal Outcome Measures

    DEEP Trial: Improvements in Select Neonatal Outcome Measures1 Primary composite endpoint in current Phase 2b/3a study of AMAG-423 Intraventricular Hemorrhage (IVH) Necrotizing Enterocolitis (NEC) Deaths Severe (grades 3 and 4) p=0.24 p=0.61 p=0.49 n=3 n=3 n=2 n=1 % of neonatal Deaths neonatal of % %

  28. Slide 28: 2020: Goals and Key Areas of Focus for AMAG

    Slide 28: 2020: Goals and Key Areas of Focus for AMAG

    2020: Goals and Key Areas of Focus for AMAG Divest Intrarosa and Work with the FDA Complete successful Drive continued Vyleesi to align with to maintain patient CEO transition Feraheme growth new strategic direction access to Makena Advance ciraparantag Pursue ex-U.S. Meet/exceed and AMAG-423 portfo

  29. Slide 29: Breakout Session: Kent Room

    Slide 29: Breakout Session: Kent Room

    Breakout Session: Kent Room © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 29

  30. Slide 30: Appendix

    Slide 30: Appendix

    Appendix 30

  31. Slide 31: Reconciliation of GAAP to Non-GAAP Preliminary Financial Results

    Slide 31: Reconciliation of GAAP to Non-GAAP Preliminary Financial Results

    Reconciliation of GAAP to Non-GAAP Preliminary Financial Results ($M) 9-Mos 2019 Q4-2019 FY 2019 GAAP operating loss ($251.6) ($22) - ($12) ($274) - ($264) Depreciation and intangible asset amortization 13.9 7.0 21.0 Stock-based compensation 13.7 5.0 18.5 Restructuring 7.4 -- 7.4 Transaction/acquisi

  32. Slide 32: Reconciliation of GAAP to Non-GAAP 2020 Financial Guidance

    Slide 32: Reconciliation of GAAP to Non-GAAP 2020 Financial Guidance

    Reconciliation of GAAP to Non-GAAP 2020 Financial Guidance ($M) 2020 Financial Guidance GAAP operating income $2 - $32 Depreciation 2 Stock-based compensation 16 Non-GAAP adjusted EBITDA $20 - $50 APPENDIX © 2020 AMAG Pharmaceuticals, Inc. All rights reserved 32

  33. Slide 33: AMAG Pharmaceuticals JP Morgan 38th Healthcare Conference January 2020

    Slide 33: AMAG Pharmaceuticals JP Morgan 38th Healthcare Conference January 2020

    AMAG Pharmaceuticals JP Morgan 38th Healthcare Conference January 2020 © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 33

Source: SEC EDGAR · 8-K filed Jan 9, 2020

More decks from AMAG Pharmaceuticals Inc